Kaku Y#, Kuwata T#*, Zahid HM, Hashiguchi T, Noda T, Kuramoto N, Biswas S, Matsumoto K, Shimizu M, Kawanami Y, Shimura K, Onishi C, Muramoto Y, Suzuki T, Sasaki J, Nagasaki Y, Minami R, Motozono C, Toyoda M, Takahashi H, Kishi H, Fujii K, Tatsuke T, Ikeda T, Yosuke M, Ueno T, Koyanagi Y, Iwagoe H, Matsushita S*. 2021. Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19. Cell Rep 36:109385.

Nomura Y, Matsuoka S, Okazaki M, Kuwata T, Matano T, Ishii H. 2021. Neutralizing Antibody Induction Associated with a Germline Immunoglobulin Gene Polymorphism in Neutralization-Resistant SIVsmE543-3 Infection. Viruses 13:1181.

Judicate GP, Barabona G, Kamori D, Mahiti M, Tan TS, Ozono S, Mgunya AS, Kuwata T, Matsushita S, Sunguya B, Lyamuya E, Tokunaga K, Ueno T. 2021. Phenotypic and Genotypic Co-receptor Tropism Testing in HIV-1 Epidemic Region of Tanzania Where Multiple Non-B Subtypes Co-circulate . Front Microbiol 12:1788.

Katsuya H, Cook LBM, Rowan AG, Melamed A, Turpin J, Ito J, Islam S, Miyazato P, Jek Yang Tan B, Matsuo M, Miyakawa T, Nakata H, Matsushita S, Taylor GP, Bangham CRM, Kimura S, Satou Y. 2021. Clonality of HIV-1– and HTLV-1–Infected Cells in Naturally Coinfected Individuals. J Infect Dis https://doi.org/10.1093/infdis/jiab202.

Yamamoto H, Sugawara Y, Sambommatsu Y, Shimata K, Yoshii D, Isono K, Honda M, Yamashita T, Matsushita S, Inomata Y, Hibi T. 2020. Living donor domino liver transplantation in a hepatitis C virus/human immunodeficiency virus-coinfected hemophilia patient: a case report. Surg Case Reports 6:184.

Matsuoka S#, Kuwata T#*, Ishii H#, Sekizuka T, Kuroda M, Sano M, Okazaki M, Yamamoto Y, Shimizu M, Matsushita S, Seki Y, Saito A, Sakawaki H, Hirsch V, Miura T, Akari H, Matano T*. A potent anti-simian immunodeficiency virus neutralizing antibody induction associated with a germline immunoglobulin gene polymorphism in rhesus macaques.  J Virol. 2021, 95 (7):e02455-20

Kobayakawa T, Tsuji K, Konno K, Himeno A, Masuda A, Yang T, Takahashi K, Ishida Y, Ohashi N, Kuwata T, Matsumoto K, Yoshimura K, Sakawaki H, Miura T, Harada S, Matsushita S and Tamamura H. Hybrids of Small-Molecule CD4 Mimics with Polyethylene Glycol Units as HIV Entry Inhibitors, Journal of Medicinal Chemistry 2021, 64, 3, 1481–1496 January 26, 2021  

Kaku, Y., Kuwata, T.*, Gorny M.K., Matsushita, S. Prediction of contact residues in anti-HIV neutralizing antibody by deep learning . Japanese Journal of Infectious Diseases, Jpn.J.Infect.Dis., 73, 235-241 2020

Maeda Y, Takemura T, Chikata, Kuwata T, Terasawa H, Fujimoto R, Kuse N, Akahoshi T, Murakoshi H, Tran G, Zhang Y, Pham C, Pham A, Monde K, Sawa T, Matsushita S, Nguyen T, Nguyen K, Hasebe F, Yamashiro T, and Takiguchi M. Existence of replication-competent minor variants with different coreceptor usage in plasma from HIV-1-infected individuals. J Virol 2020; 94 (12) e00193-20.

Pisil, Y., Yazici, Z., Shida, H., Matsushita, S, Miura T. Specific Substitutions in Region V2 of gp120 env confer SHIV Neutralisation Resistance.  Pathogens. 9(3), 181, 2020.  

Alam, M., Kuwata, T., Tanaka, K., Munatsir, A., Takahama, S., Shimura, K., Matsuoka, M., Fukuda, N., Morioka, H., Tamamura, H., Matsushita, S. Synergistic inhibition of cell-to-cell HIV-1 infection by combinations of single chain variable fragments and fusion inhibitors. Biochemistry and Biophysics Reports, 20, 1006872, 2019.

Thida, W., Kuwata, T., Maeda, Y., Yamashiro, T., Tran, G.V., Nguyen, K.V., Takiguchi, M., Gatanaga, H., Tanaka, K., Matsushita, S.: The role of conventional antibodies targeting the CD4 binding site and CD4-induced epitopes in the control of HIV-1 CRF01_AE viruses. Biochemical and Biophysical Research Communications, Jan 1;508(1):46-51, 2019.

Siddiqui, R,, Suzu, S., Ueno, M., Nasser, H., Koba, R., Bhuyan, F., Noyori, O., Yasuda-Inoue, M., Hishiki, T., Sukegawa, S., Miyagi, E., Strebel, K., Matsushita, S., Shimotohno, K., Ariumi, Y. Apolipoprotein E is an HIV-1-inducible inhibitor of viral production and infectivity in macrophages. PLoS Pathogens, 14(11) e1007372, 2018.

Kobayakawa, T., Ohashi, N., Hirota, Y., Takahashi, K., Yamada, Y., Narumi, T., Yoshimura, K., Matsushita, S., Harada S, Tamamura H. Flexibility of small molecular CD4 mimics as HIV entry inhibitors. Bioorg Med Chem., 2018, 26(21),5664-5671.

Komatsu, A., Ikeda, A., Kikuchi, A., Minami, C., Tan, M., Matsushita, S. Osteoporosis-Related Fractures in HIV-Infected Patients Receiving Long-Term Tenofovir Disoproxil Fumarate: An Observational Cohort Study. Drug Saf., 2018, 41(9),843-848.

Stanoeva, K.R., König, A., Fukuda, A., Kawanami, Y., Kuwata, T., Satou, Y., Matsushita, S. Total HIV-1 DNA dynamics and influencing factors in long-term ART-treated Japanese adults: retrospective longitudinal analysis. J. AIDS, 78(2),239-247, 2018

Miyazaki, N., Sugiura, W., Gatanaga, H., Watanabe, D., Yamamoto, Y., Yokomaku, Y., Yoshimura, K., Matsushita, S.; Japanese HIV-MDR Study Group. High antiretroviral coverage and viral suppression prevalence in Japan: an excellent profile for downstream HIV care spectrum. Jpn. J. Infect. Dis. 70: 158-160, 2017. 

Tanaka, K., Kuwata, T., Alam, M., Kaplan., G, Takahama, S., Valdez, K.P.R., Roitburd-Berman, A., Gershoni. J.M., Matsushita, S. Unique binding modes for the broad neutralizing activity of single-chain variable fragments (scFv) targeting CD4-induced epitopes. Retrovirology 14: 44-59, 2017.

Ohashi N., Harada S., Mizuguchi T., Irahara Y., Yamada Y., Kotani M., Nomura W., Matsushita S., Yoshimura K., Tamamura H. Small molecular CD4 mimics containing mono-cyclohexyl moieties as HIV entry inhibitors. Chem.MedChem., 11(8):940-6, 2016.

Maruta Y., Kuwata T., Tanaka K., Alam M., Ramirez-Valdez K-P., Egami Y., Yoshiaki Suwa Y., Morioka H., Matsushita S. Cross-neutralization activity of single-chain variable fragment (scFv) derived from anti-V3 monoclonal antibodies mediated by post-attachment binding. Jpn. J. Infect. Dis.,69(5):395-404, 2016

Mizuguchi T., Harada S., Miura T., Ohashi N., Narumi T, Mori H.; Irahara Y; Yamada Y.; Nomura W., Matsushita S., Yoshimura K, Tamamura H. Minimally cytotoxic CD4 mimic as an HIV entry inhibitor. Bioorg Med Chem Lett. 26:397-400, 2016.

Kuwata, T., Enomoto, I., Baba, M. and Matsushita S. Incompatible natures of HIV-1 envelope in resistance to the CCR5 antagonist cenicriviroc and neutralizing antibodies．Antimicrobial Agents and Chemotherapy (AAC), 60(1), 437-450, 2016.　doi: 10.1128/AAC.02285-15

Ramirez, K., Kuwata, T., Maruta, Y., Tanaka, K., Alam, M., Yoshimura, K., Matsushita, S. Complementary and synergistic activities of anti-V3, CD4bs and CD4i antibodies derived from a single individual can cover a wide range of HIV-1 strains. Virology, 475, 187-203, 2015.　doi:10.1016/j.virol.2014.11.011

Matsushita, S., Yoshimura, K., Ramirez, k., Pisupati, J., Murakami, T., the KD-1002 Study Group. Passive transfer of neutralizing mAb KD-247 reduces plasma viral load in patients chronically infected with HIV-1. AIDS, 29(4), 453-462, 2015.
doi: 10.1097/QAD.0000000000000570

Boonchawalit, S., Harada, S, Shirai, N., Gatanaga, H., Oka, S., Matsushita, S., and Yoshimura, K. Impact of maraviroc-resistant mutation M434I in the C4 region of HIV-1 gp120 on sensitivity to antibody-mediated neutralization. Jpn. J. Infec.t Dis.,69, 236-243, 2015.

Kirby, K.A., Ong Y.T., Hachiya, A., Laughlin, T.G., Chiang, L.A., Pan, Y., Moran, J.L., Marchand, B., Singh, K., Gallazzi, F., Quinn, T.P., Yoshimura, K., Murakami, T., Matsushita, S., Sarafianos, S.G.. Structural basis of clade-specific HIV-1 neutralization by humanized anti-V3 monoclonal antibody KD-247. The FASEB Journal, 29(1), 70-80, 2015.

Yoshimura, K., Harada, S., Boonchawalit, S., Kawanami, Y., and Matsushita, S. Impact of maraviroc-resistant and low-CCR5- adapted mutations induced by in vitro passage on sensitivity to anti-envelope neutralizing antibodies. Journal of General Virology, 95, 1816-1826, 2014.

Otsuki, H., Hishiki, T., Miura, T., Hashimoto, C., Narumi, T., Tamamura, H., Yoshimura, K., Matsushita, S., and Igarashi, T. Generation of a replication-competent simian-human immunodeficiency virus, the neutralization sensitivity of which can be enhanced in the presence of a small-molecule CD4 mimic. J. Gen. Virol. 94: 2710-2716, 2013.

Hashimoto, C., Narumi, T., Otsuki, H., Hirota, Y., Arai, H., Yoshimura, K., Harada, S., Ohashi, N., Nomura, W., Miura, T., Igarashi, T., Matsushita, S. and Tamamura, H. A CD4 mimic as an HIV entry inhibitor: Pharmacokinetics. Bioorg. Med. Chem. 21: 7884-7889 , 2013.

The Mind Exchange Working Group (Antinori A, Arendt G, Grant I, Matsushita S, et al.) Assessment, Diagnosis, and Treatment of HIV-Associated Neurocognitive Disorder: A Consensus Report of the Mind Exchange Program. Clin Infect Dis. 56(7):1004 -1017, 2013

Harada S, Yoshimura K, Yamaguchi A, Yusa K, Matsushita S. Impact of antiretroviral pressure on selection of primary HIV-1 envelope sequences in vitro.  J. Gen. Virol. 94:933-943, 2013.

Kuwata T, Takaki K, Yoshimura K, Enomoto I, Wu F, Ourmanov KI, Hirsch VM, Yokoyama M, Sato H, Matsushita S. Conformational Epitope Consisting of the V3 and V4 Loops as a Target for Potent and Broad Neutralization of Simian Immunodeficiency Viruses.  J. Virol. 87:5424-5346, 2013.

Narumi T, Arai H, Yoshimura K, Harada S, Hirota Y, Ohashi N, Hashimoto C, Nomura W, Matsushita S, Tamamura H.: CD4 mimics as HIV entry inhibitors: lead optimization studies of the aromatic substituents.  Bioorganic & Medicinal Chemistry. 21:2518-2526, 2013 .

Kuwata T, Takaki K, Enomoto I, Kazuhisa Y, and Matsushita S. Increased infectivity in human cells and resistance to antibody-mediated neutralization by truncation of the SIV gp41 cytoplasmic tail.   Frontiers in Microbiology/Virology. 4:1-7, 2013.

Yokoyama M, Naganawa S, Yoshimura K, Matsushita S, Sato H. Structural Dynamics of HIV-1 Envelope Gp120 Outer Domain with V3 Loop. PLoS ONE. 7(5): e37530, 2012.

Ong YT, Kirby KA, Hachiya A, Chiang LA, Marchand B, Yoshimura K, Murakami T, Singh K, Matsushita S, Sarafianos SG. Preparation of biological active single-chain variable antibody fragments that target the HIV-1 gp120 v3 loop. Cellular and Molecular Biology. 58: 71-79, 2012

Honda M, Ishisaka M, Ishizuka N, Kimura S, Oka S and behalf of Japanese Anti-HIV-1 QD Therapy Study Group. Open-Label Randomized Multicenter Selection Studyof Once Daily Antiretroviral Treatment Regimen Comparing Ritonavir-Boosted Atazanavir to Efavirenz with Fixed-Dose Abacavir and Lamivudine. Internal Medicine. 50: 699-705,2011.

Narumi, T., Arai, H.,Yoshimura, K.,Harada, S., Nomura, W., Matsushita, S., Tamamura. H. Small molecular CD4 mimics as HIV entry inhibitors. Bioorg Med Chem , 19: 6735-6742 ,2011.

Narumi, T., Ochiai, C., Yoshimura, K., Harada, S., Tanaka,T., Nomura,W., Arai, H., Ozaki, T., Ohashi, N., Matsushita, S., Tamamura, H. :CD4mimics targeting the HIV entry mechanism and their hybrid molecules with a CXCR4 antagonist. Bioorganic & Medicinal Chemistry Letters.　5853- 5858, 2010.

Yoshimura, K., Harada, S., Shibata, J., Hatada, M., Yamada, Y., Ochiai, C., Tamamura, H., Matsushita, S. :Enhanced exposure of human immunodeficiency virus type 1 primary isolate neutralization epitopes through binding of CD4 mimetic compounds. J. Virol. 84:7558-7568, 2010.

Hatada, M., Yoshimura, K., Harada, S., Kawanami, Y., Shibata, J., Matsushita S. HIV-1 evasion of a neutralizing anti-V3 antibody involves acquisition of a potential glycosylation site in V2. J. Gen. Virol. 91: 1335-1345, 2010.　

Yamada, Y., Ochiai, C., Yoshimura, K., Tanaka, T., Ohashi, N., Narumi, T., Nomura, W., Harada, S., Matsushita, S., Tamamura, H. CD4 mimics targeting the mechanism of HIV entry. Bioorganic & Medicinal Chemistry Letters 20: 354–358, 2010.

Ryo, A., Tsurutani, N., Ohba, K., Kimura, R., Komano, J., Nishi, M., Soeda,H., Hattori,S., Perrem, K., Yamamoto, M., Chiba, J., Mimaya, J., Yoshimura, K., Matsushita, S., Honda, M., Yoshimura, A., Sawasaki, T., Aoki, I., Morikawa, Y., and Yamamoto, N. SOCS1 is an inducible host factor during HIV-1 infection and regulates the intracellular trafficking and stability of HIV-1 Gag. Proc Natl Acad Sci U S A. 105:294-299, 2008.

Ikeda T, Ohsugi T, Kimura T, Matsushita S., Maeda Y, Harada S, Koito A. The anti-retroviral potency of APOBEC1 deaminase from small animal species. Nuleic Acids Research, 36(21): 6859-6871, 2008.

Ikeda T, Shibata J, Yoshimura K,Koito A, Matsushita S. Recurrent HIV-1 integration at the BACH2 locus in resting CD4+ T cell populations during effective HAART.J. Infect. Dis.195:716-725, 2007 .

Shibata J, Yoshimura K, Honda A.,Koito A, Murakami T. Matsushita S. Impact of V2 mutations for escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary HIV-1 isolate.　J. Virol. 81:3757-3768,2007

Gatanaga H, Hayashida T, Tsuchiya K, Yoshino M, Kuwahara T, Tsukada H, Fujimoto K, Sato I, Ueda M, Horiba M, Hamaguchi M, Yamamoto M, Takata N, Kimura A, Koike T, Gejyo F, Matsushita S, Shirasaka T, Kimura S, Oka S.: Successful efavirenz dose reduction in HIV-1-infeccted individuals with cytochrome P450 2B6*6 and *26. Clinical Infectious Diseases., 45: 1230-1237, 2007.

Nakayama E.E., Carpentier W, Costagliola D., Shioda T., Iwamoto A., Debre P, Yoshimura K, Autran B, Matsushita S, Theodorou I. Wild type and H43Y variant of human TRIM5α show similar anti-human immunodeficiency virus type 1 activity both in vivo and in vitro. Immunogenetics 59:511-515, 2007.

Eda Y, Takizawa M, Murakami T., Maeda H., Kimachi K., YonemuraH, Koyanagi S, Shiosaki K, Higuchi H, Makizumi K, Nakashima T ,Osatomi K., Tokiyoshi S, Matsushita S, Yamamoto N. Honda M.　Sequential immunization with V3 peptides from primary HIV-1 produces　cross-neutralizing antibodies against primary isolates with matching narrow　neutralization sequence motif.J. Virol.　80:5552-5562,2006.

Eda Y, Murakami T, Ami Y, Nakasone T, Takizawa M, Someya K,　Kaizu M, Izumi Y., Yoshino, N., Matsusita, S.,Higuchi, H., Matsui, H., Shinohara, K., Takeuchi, H., Koyanagi, S., Yamamoto, N. and Honda M. Anti-V3　humanized antibody KD-247 effectively suppresses ex vivo generation of human　immunodeficiency virus type 1 and affordssterile protection of monkeys　against a heterologous simian/human immunodeficiency virus infection. J. Virol.　80:5563-5570,　2006

Davis DA, Brown CA, Singer KE., Wang V, Kaufman J, Stahl SJ, Wingfield P, Maeda K, Harada S, Yoshimura K, Kosalaraksa, P, Mitsuya H, Yarchoan R　Antiviral Res.　72:89-99, 2006

Yoshimura K, Shibata J, Kimura T, Honda A, Maeda Y, Koito A, Murakami T, Mitsuya H, Matsushita S.　Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favorable synergism with anti-CCR5 inhibitors. AIDS　.20:2065-2073, 2006.

Matsushita S., Yoshimura, K., Kimura T., Kamihira, A., Takano, M., Eto, K., Shirasaka, T., Mitsuya, H., Oka, S.: Spontaneous recovery of hemoglobin and neutrophil levels in Japanese patients on a long-term CombivirR containing regimen. J.Clin.Virol. 33:188-193, 2005

Sakaguchi N, Kimura T., Matsushita S, Fujimura S, Shibata J, Araki M, Sakamoto T, Minoda S, and Kuwahara K.Generation of high-affinity antibody against T cell- dependent antigen in ganp gene- transgenic mouse. J. Immunol. 174:4485-4494，2005.

Matsushita S, Takahama S., Shibata J., Kimura T., Shiozaki K., Eda Y., Koito A., Murakami T, and Yoshimura K. Ex vivo neutralization of HIV-1 quasispecies by a broadly reactive humanized monoclonal antibody KD247.　Human Antibodies. 14:80-88,　2005

Tamiya　S., Mardy　S., Kavlick　M.F., Yoshimura K, Mistuya H. 　Amino acid insertions near Gag cleavage sites restore the otherwise compromised replication of human immunodeficiency virus type 1 variants resistant to protease inhibitors.　J. Virol. 78:12030-12040, 2004.

Koito A, Shigekane H, Matsushita S.　Ability of small animal cells to support post integration phase of human immunodeficiency virus type 1 replication. Virology, 305:181-191,　2003.

Koito A,Kameyama Y, Cheng-Mayer C, Matsushita S. Susceptibility of mink (Mustera vision)-derived cells to replication by human immunodeficiency virus type-1. J Virol, 77:5109-511,　2003

Yoshimura K, Ido E., Akiyama H, Kimura T, Aoki M, Suzuki H., Mitsuya H, Hayami M, Matsushita S. The impact of highly active antiretroviral therapy by the oral route on the CD8 subset in monkeys infected chronically with SHIV89.6P. J Virol Methods. 112:121-128, 2003.

Gatanaga, H., Suzuki, Y., Tsang, H., Yoshimura, K., Kavlick, M.F., Nagashima, K., Gorelick, R.J., Mardy, S., Tang, C., Summers, M.F., Mitsuya, H.: Amino acid substitutions in gag protein at non-cleavage sited are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors. J. Biol. Chem. 277:5952-5961, 2002.

Matsushita, S. Kimura, T. Advance in treatment strategy and immune reconstruction against HIV-1 infection. Microbiol. Immunol., 46(4):231-239, 2002.

Wang FX, Kimura T, Nishihara K., Yoshimura K.,Koito A, Matsushit S. Emergence of autologous neutralization-resistant variants from pre existing quasispecies during viral-rebound of human immunodeficency virus type-1 infected patients under treatment of highly active anti retroviral therapy (HAART) . J Infect Dis, 185:608-617,　2002.

Kimura T, Yoshimura K., Nishihara K., Maeda Y, Matsumi S,Koito A, Matsushita S. Reconstitution of spontaneous neutralizing antibody response against autologous HIV-1 in chronically infected patients during highly active antiretroviral therapy. J. Infect. Dis., 185:53-60, 　2002.

Yoshimura K, Kato R , Kavlick MF, Nguyen A, Maroun V, Maeda K., Hussain K., Ghosh A., Erickson J, Mitsuya H. A Potent Protease Inhibitor (PI) UIC-94003 Interacting with Main Chains of HIV Protease Active Site Amino Acids and the Development of a Novel Mutation A28S in the Protease of UIC-94003-Resistant HIV. J Virol, 76:1349-1357,　2002.

Maeda, K., Yoshimura, K., Shibayama, S., Habashita, H., Tada, H., Sagawa, K., Miyakawa, T., Aoki, M., Fukushima, D., and Mitsuya, H. Novel Low Molecular Weight Spirodiketopiperazine Derivatives Potently Inhibit R5 HIV-1 Infection through Their Antagonistic Effects on CCR5. J. Biol. Chem. 276:35194-35200, 2001.

Ikegawa M, Matsumoto K, Herrmann S, Iwamoto A, Nakamura T, Matsushita S, Nakamura T, Honjo T, Tashiro K: Elevated plasma SDF-1 protein level in the progression of HIV-1 infection/AIDS. AIDS Res Hum Retrov. 17(7):587-595, 2001

Sei, S., Yang, Q. E., O’Neill, D., Yoshimura, K., Nagashima, K., and Mitsuya, H. Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain. J. Virol. 74:4621-33, 2000.

Falloon, J., Piscitelli, S., Vogel, S., Sadler, B., Mitsuya, H., Kavlick, M. F., Yoshimura, K., Rogers, M., LaFon, S., Manion, D. J., Lane, H. C., and Masur, H. Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease- inhibitor regimen: pharmacokinetic drug interactions and antiviral activity. Clin. Infect. Dis. 30:313-308, 2000.

Ohrui, H., Kohgo, S., Kitano, K., Sakata, S., Kodama, E., Yoshimura, K., Matsuoka, M., Shigeta, S., and Mitsuya, H. Syntheses of 4′-C-Ethynyl-beta-D-arabino- and 4′-C-Ethynyl-2’deoxy- beta-D-ribo-pentofuranosylpyrimidines and -purines and Evaluation of Their Anti-HIV Activity. J. Med. Chem. 43:4516-4525, 2000.

Murakami T, Nakajima N, Nakamura T, Hara A., Uyama E., Mita S, Matsushita S, Uchino M. Parkinsonian symptoms as an initial manifestation in a Japanese patient with acquired immunodeficiency syndrome and toxoplasma infection. Internal Medicine 39, 1111-1114, 2000.

Tugarinov V, Zvi A, Levy R, Hayek Y, Matsushita S, Anglister J. NMR structure of an anti gp-120 antibody complex with a V3-peptide reveals a surface important for co-receptro binding. Structure 8, 385-395. 2000.

Matsushita S. Current status and future issues in the treatment of HIV infection. Int. J. Hematol. 72(1):20-27, 2000

Maeda Y, Foda M, Matsushita S, Harada S. Involvement of both V2 and V3 region of CCR5-tropic human immunodeficiency virus type-1 envelope for reduced sensitivity to macrophage inflammatory protein α　J Virol 74(4), 1787-1793, 2000

Yoshimura K, Kato R, Yusa K, Kavlick MF, Maroun V, Nguyen A, Mimoto T, Ueno T, Shintani M, Falloon J, Masur H, Hayashi H, Erickson J, Mitsuya H. JE-2147: a dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1. Proc Natl Acad Sci USA. 96:8675-80., 1999.

Yoshimura K,Feldman R, Kodama E, Kavlick MF, Qiu YL, Zemlicka J, Mitsuya H. In vitro induction of human immunodeficiency virus type 1 variants resistant to phosphoralaninate prodrugs of Z-methylenecyclopropane nucleoside analogues. Antimicrob Agents Chemother. 43:2479-83, 1999.

Matsumi S, Maeda Y, Kimura T, Matsushita S. Effect of the Th1 and Th2 stimulatory cytokines, IL-12 and IL-4, on HIV-1 specific CTL activity. 12th World AIDS Conference, Appendix 5: 45-50, 1998.

Wang J, Harada K., Matsushita S, Matsumi S, Zhang Y, Shioda T, Nagai Y, Matsushima K. IL-4 and a glucocorticoid up-regulate CXCR4 expression on human CD4+ T lymphocytes and enhance HIV-1 replication. J. Leukocyte Biology., 64:642-649,1998.

Shoji S, Kazuchika K, Ogata A, Yamataka K., Mukai K., Uda A., Harano S, Matsushita S, Misumi S. An allisteric drug, o’o’-bismyristoyl thiamine disulfide, suppresses HIV-1 replication through prevention of nuclear translocation of both HIV-1 tat and NF-ΚB. Biochem. Biophys. Res. Commun., 249, 745-753, 1998.

Hakata Y, Umemoto T., Matsushita S,　Shida H. Involvement of human CRM1 (Exportin 1) in the export and multimerization of the Rex protein of the human T-cell leukemia virus type 1. J. Virol. 72: 6602-6607, 1998.